04 Jun 2026

CRC Research Update — June 04, 2026

Creator: The CRC Digest
Published: 2026-06-04T14:30:16Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

BREAKWATER trial shows survival benefit for BRAF V600E-mutant metastatic CRC
Phase III trial reports progression-free and overall survival analyses for first-line encorafenib plus cetuximab plus FOLFIRI in patients with BRAF V600E-mutant metastatic colorectal cancer. (Journal of Clinical Oncology)
Fruquintinib plus chemotherapy tested against bevacizumab in second-line metastatic CRC
Prospective, multicenter, randomized phase III trial evaluates efficacy and safety of fruquintinib combined with chemotherapy versus bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer. (Journal of Clinical Oncology)
KRAS G12C mutations show distinct prognosis in metastatic CRC
Systematic review and meta-analysis establishes the prognostic significance of KRAS G12C mutations compared to non-G12C RAS mutations in metastatic colorectal cancer, addressing conflicting evidence from smaller studies. (The Oncologist)
Younger individuals with family history show increased advanced adenoma risk
Study of 409 patients undergoing early screening colonoscopy due to first-degree relative with advanced polyps found increased prevalence of advanced adenomas in younger individuals, supporting current early screening guidelines. (Gastroenterology and Hepatology Advances)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Family history drives earlier screening need
Patients with a first-degree relative diagnosed with advanced polyps before age 60 showed significantly increased prevalence of advanced adenomas when screened early, validating guidelines recommending colonoscopy at age 40 or 10 years before relative's diagnosis.

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, and more

Adjuvant chemotherapy evaluated in high-risk stage II MSI-H/dMMR colon cancer
Multicenter retrospective analysis of 192 patients evaluated outcomes comparing adjuvant chemotherapy versus surgery only in high-risk stage II MSI-H/dMMR colon cancer, with 5-year relapse-free survival as the primary endpoint, addressing discordant international guidelines on this population.
Cholesterol pathway rewiring drives KRAS inhibitor resistance
Study shows enhancer remodeling activates the mevalonate pathway to sustain MAPK signaling despite KRAS inhibition in colorectal cancer, and that statins can block KRAS membrane localization to overcome resistance.

Research continues to refine treatment strategies and identify patients who benefit most from targeted approaches.

CRC Research Update

Subscribe to The CRC Digest